Procept Biorobotics Corp

Health Care
Medical/Dental Instruments
www.procept-biorobotics.com

Moat Score
Safety Score

Market Cap $2.92B
PE -32
Debt $52.00M
Cash $319.25M
EV $2.66B
FCF -$88.21M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$90.19M
EBIT	-$96.40M
ROE	-23%
ROA	-19%
FCF	-$88.21M
Equity	$389.16M
Growth Stability	1
PE	-32.41
PB	7.51
P/FCF	-33.14
P/S	11.73
Price/Cash	0.11
Debt/Equity	0.13
Debt/FCF	-0.59
Net Margins	-36%
Gross Margins	63%
Op. Margins	-39%
Sales Growth YoY	55%
Sales Growth QoQ	1%
Sales CAGR	76%
Equity CAGR	9%
Earnings Growth YoY	-5%

Earnings Growth QoQ	31%
Sales CAGR 5Y	82%
Equity CAGR 5Y	9%
Earnings CAGR 3Y	78%
Sales CAGR 3Y	78%
Equity CAGR 3Y	24%
Market Cap	$2.92B
Revenue	$249.12M
Assets	$519.38M
Total Debt	$52.00M
Cash	$319.25M
Shares Outstanding	54.92M
EV	2.66B
Moat Score	2%
Safety Score	65%
Working Capital	413.73M
Current Ratio	8.95
Gross Profit	$156.23M
Shares Growth 3y	9%
Equity Growth QoQ	-3%
Equity Growth YoY	47%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are primarily based in the United States. Its revenue is primarily generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

SEC Filings

Direct access to Procept Biorobotics Corp (PRCT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Procept Biorobotics Corp compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Procept Biorobotics Corp compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Procept Biorobotics Corp Discounted Cash Flow

Fully customizable DCF calculator online for Procept Biorobotics Corp.

Years

Calculation mode

= -$882M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$88M	-$882M
DCF		-$80M	-$73M	-$66M	-$60M	-$55M	-$50M	-$45M	-$41M	-$37M	-$34M	-$340M
Value	-$882M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-687%	-174%	-116%	-78%	-41%	-36%
ROA	-	-16%	-26%	-27%	-18%	-19%
ROE	-	-22%	-44%	-38%	-23%	-23%

Bad Net Margins (-35.77%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-0.86	-0.63	-0.39	-0.5	-0.59
Debt over Equity	-0.3	0.19	0.26	0.19	0.13	0.13
Growth Stability	-	-	-	-	-	1

Good Debt/FCF ratio (-0.59)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.13)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	347%	118%	82%	65%	82%
Earnings YoY growth	-	13%	46%	22%	-14%	-
Equity YoY growth	-	-246%	-26%	42%	43%	9%
FCF YoY growth	-	19%	43%	60%	-22%	-